[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"clinically-isolated-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:clinically-isolated-syndrome":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,49,77,109,141,170,194,222,250],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100443689","autoimmune-intervention-mastery-course-study-100443689",false,"NCT05057676","Autoimmune Intervention Mastery Course Study","Evaluation of an Online Course Designed to Support the Adoption of Healthier Diet and Self-Care Routines in Multiple Sclerosis Patients","AIM","Inclusion Criteria:\n\n* self-reported multiple sclerosis\n* self-reported clinically isolated syndrome\n\nOR self-reported post-acute sequelae of COVID (PASC), also known as long COVID, with a confirmed laboratory test of COVID-19 infection, persisting fatigue and neuropsychiatric symptoms for longer than 6 months after confirmation of COVID diagnosis,\n\nOR self-reported diagnosis of fibromyalgia as documented by their treating specialist or primary care provider,\n\nExclusion Criteria:\n\n\\-","ALL","18 Years","100 Years",{"count":21,"type":22},400,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this project is to critically evaluate the effectiveness of using an online program to improve diet and self-care in patients with multiple sclerosis (MS), clinically isolated syndrome (CIS), fibromyalgia, post acute sequela of covid, and cancer in remission with persisting fatigue.",[28,29,30,31,32],"Multiple Sclerosis","Clinically Isolated Syndrome","Fibromyalgia","Post Acute Sequelae of COVID-19","Cancer in Remission With Persisting Fatigue",[34,35],"diet","self care","RECRUITING","2026-03-09",{"date":39,"type":40},"2026-03-11","ACTUAL",{"date":42,"type":40},"2021-12-01",{"date":44,"type":22},"2027-12-01",{"name":46,"class":47},"Terry L. Wahls","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":48},"100423805","pathogenicity-of-b-and-cd4-t-cell-subsets-in-multiple-sclerosis-100423805","NCT04798651","Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis","T4MS","Inclusion Criteria:\n\n* male or female subjects ;\n* Age ≥ 18 years;\n* subjects with MS defined by 2010 revised McDonald criteria or presenting a clinical isolated syndrome;\n* patients for which a blood draw and \u002F or lumbar puncture to collect CSF is performed for diagnostic or therapeutic purpose;\n* affiliated to an health insurance system;\n* and who agree to participate in the study.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women,\n* patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent)",{"count":57,"type":22},150,[25],"The study aims at identifying the type of B and CD4 T cell subsets with pathogenic properties in the different clinical forms of multiple sclerosis. This research might open new therapeutic approaches for the treatment of multiple sclerosis particularly progressive MS.",[28,29],[62,63,64,65,66,67],"Autoimmune Diseases of the Nervous System","Multiple sclerosis","clinically isolated syndrome","lymphoid cells","CD4 T cells","B cells","2026-01-30",{"date":70,"type":40},"2026-02-03",{"date":72,"type":40},"2021-09-30",{"date":74,"type":22},"2026-09",{"name":76,"class":47},"University Hospital, Bordeaux",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":92,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":48},"100614536","clinnova-ms-a-prospective-cohort-study-of-patients-with-multiple-sclerosis-a-trans-regional-digital-health-effort-unlocking-the-potential-of-artificial-intelligence-and-data-science-in-health-care-100614536","NCT07280871","Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis: A Trans-regional Digital Health Effort Unlocking the Potential of Artificial Intelligence and Data Science in Health Care","Clinnova-MS","Inclusion Criteria:\n\n1. Signed informed consent form\n2. ≥ 18 years of age\n3. Willing and able to comply with the protocol for the duration of the study including data and samples collection as well as study visits and examinations.\n4. Diagnosed with MS according to the revised McDonald criteria 2017 or revised McDonald criteria 2024, all clinical forms inclusive (CIS, RRMS, SPMS, PPMS) AND early disease stages (\\\u003C 3 years), OR presenting at hospital for evaluation of a change in therapy (flare) OR transitioning phase to progressive disease as evaluated based on EDSS.\n\nExclusion Criteria:\n\n1. Diagnosis uncertain (no fulfilment of inclusion criteria)\n2. Any condition that could potentially hamper the compliance with the study protocol, including study procedures and study visits such as mental disability that makes it difficult or impossible to answer questionnaires.\n3. Not fluent in any of the following languages: French, English or German.\n4. Known pregnancy before the inclusion into the study",{"count":85,"type":22},100,"OBSERVATIONAL","The Clinnova-Multiple Sclerosis (MS) study is part of the Clinnova program (NCT06526364; NCT06235684 and NCT05733702), which seeks to advance precision medicine and the digitalization of healthcare through high-quality, interoperable health data.\n\nThis program focuses on people with multiple sclerosis (MS) and aims to identify objective surrogate markers derived from clinical, epidemiological, imaging, and omics data that can predict disease activity, such as progression or relapses.\n\nBy combining data science and artificial intelligence, the project seeks to improve patient stratification, support personalized therapeutic decisions, and provide insights into the mechanisms underlying treatment response and disease progression.\n\nAlthough many therapies are available for MS, it remains challenging to determine the most appropriate strategy for each patient and to prevent long-term disability. Current treatments mainly target relapses and inflammation, with limited effects on chronic progression. Clinnova-MS will collect and analyze real-world and research data to better understand variability in disease activity and treatment outcomes, enabling more precise, evidence-based care within the standard of care. This study represents the first step toward the broader Clinnova objective: developing sustainable, personalized, and preventive healthcare for people living with MS.",[89,90,29,91],"Multiple Sclerosis, Relapsing-Remitting","Multiple Sclerosis, Chronic Progressive","Primary Progressive Multiple Sclerosis",[93,94,95,96,97],"AI","Machine Learning","MS","phenotyping","personalised medicine","NOT_YET_RECRUITING","2025-12-31",{"date":101,"type":40},"2026-01-06",{"date":103,"type":22},"2026-06",{"date":105,"type":22},"2040-06",{"name":107,"class":108},"Luxembourg Institute of Health","OTHER_GOV",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":117,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":120,"conditions":121,"keywords":125,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":140},"100537663","clinical-impact-through-ai-assisted-ms-care---a-retrospective-multi-center-observational-study-100537663","NCT06280755","Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.","Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study","RECLAIM","Inclusion criteria:\n\n* Patients must have a confirmed diagnosis of MS, NMOSD, MOGAD, CIS or RIS.\n* Patient (or patient's legal representative) has previously signed and dated an informed consent form (ICF) for the secondary use of their data, or assent form. Alternatively, the secondary use of the patient's data is allowed following Institutional Review Board (IRB)\u002FEthical Committee (EC) approval in accordance with national and local subject privacy regulations.\n\nExclusion criteria:\n\n* Patients under 18 years of age will be excluded.\n* Other unspecified reasons that, in the opinion of the Investigator or Joint Steering Committee, make the patient unsuitable for participation in the study.",true,{"count":119,"type":22},7000,"The RECLAIM study aims to gather a centralized and harmonized dataset, enabling the secondary use of data for building AI-based models that will support diagnosis and prognosis of individual Multiple Sclerosis patient's disease course and treatment response in a real-world setting. Additionally, the data will be used to generate further insights on Multiple Sclerosis progression as well as to develop the tools to monitor this progression.",[28,122,123,124,29],"NMO Spectrum Disorder","Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease","Radiologically Isolated Syndrome",[28,126,127,128,129],"Prognosis","Progression","AI models","disease worsening","2025-12-05",{"date":132,"type":40},"2025-12-12",{"date":134,"type":40},"2024-03-01",{"date":136,"type":22},"2027-04",{"name":138,"class":139},"icometrix","INDUSTRY",3,{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":23,"phases":152,"briefSummary":153,"conditions":154,"keywords":155,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":48},"100551072","predictive-value-of-the-optic-nerve-involvement-in-clinically-isolated-syndrome-100551072","NCT06455332","Predictive Value of the Optic Nerve Involvement in Clinically Isolated Syndrome","Evaluation of the Predictive Value of the Optic Nerve Involvement at the Stage of Clinically Isolated Syndrome, for the Diagnosis of Clinically Definite Multiple Sclerosis and the Delay of Second Relapses' Occurrence","HdeFIMS","Inclusion Criteria:\n\n* Patients between 18 and 55 years old\n* Occurrence of CIS ≤ 6 months\n* With two T2 hypersignals on brain\u002Fspinal cord MRI suggestive of MS or with oligoclonal bands\n* Giving their written informed consent\n\nExclusion Criteria:\n\n* Pathological conditions that may skew the optic nerve MRI and\u002For retinal OCT (diabetes mellitus, glaucoma, retinopathy, ametropia \\>6 dioptria)\n* Past history of MS relapses\n* Extensive myelitis (\\>3 vertebral bodies)\n* Bilateral optic neuritis without T2 lesions suggestive of MS\n* Contra-indication to MRI, gadolinium injection\n* Pregnancy, breast-feeding\n* Patients unable to consent","55 Years",{"count":151,"type":22},200,[25],"Optic neuritis (ON) represents around 30% of clinical presentation of clinically isolated syndrome (CIS). Asymptomatic optic nerve involvement is very frequent in all stage of multiple sclerosis (MS) disease including the CIS. However, optic nerve is still not part of MS diagnosis criteria. The main objective of our regional and multicenter study is to evaluate the prognostic value of optic nerve involvement at the earliest clinical stage of MS (=CIS) for the diagnosis of clinically definite MS (2nd clinical relapse) and the delay until the 2nd relapse.",[29,28],[156,63,157,158,159,160],"Clinically isolated syndrome","MRI","Optical coherence tomography","Optic nerve","Diagnostic criteria","2025-08-19",{"date":163,"type":40},"2025-08-24",{"date":165,"type":40},"2025-07-17",{"date":167,"type":22},"2028-07-01",{"name":169,"class":47},"University Hospital, Lille",{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":117,"sex":177,"minAge":18,"maxAge":178,"enrollmentInfo":179,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":181,"conditions":182,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":48},"100588355","pregnancy-registry-infants-serummilk-analysis-prisma-100588355","NCT06940323","Pregnancy Registry, Infants, Serum\u002FMilk Analysis (PRISMA)","Pregnancy Registry, Infants, Serum\u002FMilk Analysis (PRISMA): Pregnancy Registry for Women With Chronic Conditions","Inclusion Criteria:\n\n* Pregnant or contemplating pregnancy\n* Female, aged 18 to 64 years\n* Diagnosis of one of the following conditions:\n* Clinically Isolated Syndrome (CIS) or Multiple Sclerosis (MS), based on the 2010 McDonald Criteria\n* Neuromyelitis Optica Spectrum Disorder (NMOSD)\n* Inflammatory Bowel Disease (IBD)\n* Rheumatoid Arthritis (RA)\n* Myasthenia Gravis\n* Lupus\n* Other chronic neurological conditions\n* Willing to provide biosamples and\u002For complete surveys at specified timepoints\n* Women without a chronic condition who are pregnant or contemplating pregnancy (as part of the control group)\n\nExclusion Criteria:\n\n\\- Unwillingness to provide informed consent","FEMALE","64 Years",{"count":180,"type":22},250,"PRISMA, is a pregnancy registry study, focused on comprehensively collecting information about pregnancy in women with chronic neurological conditions from across the United States and internationally.\n\nDepending on their specific condition (MS, CIS, NMOSD, or other) and their specific treatment, participants will be asked to contribute to different aspects of the study. (1) The biosamples will be blood, breast milk, infant stool, maternal stool and vaginal swab samples, collected at specific time points. (2) The online surveys will be collected at specific time points. All study activities will be discussed with participants upon enrollment.\n\nBy collecting this information, the investigators hope to gain deeper insights into the relationship between pregnancy, the neurological condition, and maternal and infant health. For example, one of the sub-studies focuses on breast milk collection for women planning postpartum treatment with Ocrevus, Rituxan, Briumvi or Kesimpta.\n\nThis study is fully remote and all sample collection is optional, so participants can choose which types of samples they wish to provide. For blood draws, participants can schedule a home visit through ExamOne, making participation even more convenient.\n\nThe investigators aim to enroll women with chronic neurological conditions who are planning pregnancy, currently pregnant, or within one year postpartum.",[28,29,183,184],"NMOSD","Myasthenia Gravis","2025-04-30",{"date":187,"type":40},"2025-05-04",{"date":189,"type":40},"2017-03-21",{"date":191,"type":22},"2035-06",{"name":193,"class":47},"University of California, San Francisco",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":201,"enrollmentInfo":202,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":204,"conditions":205,"keywords":210,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":48},"100557708","sun-yat-sen-cohort-of-cns-idiopathic-inflammatory-demyelinating-diseases-100557708","NCT06541626","Sun Yat-Sen Cohort of CNS Idiopathic Inflammatory Demyelinating Diseases","Sun Yat-Sen Prospective Cohort Study of Central Nervous System Idiopathic Inflammatory Demyelinating Diseases","Inclusion Criteria:\n\n1. Patients aged 18-65 years with central nervous system idiopathic inflammatory demyelinating diseases (CNS IIDD);\n2. The clinical syndrome of the attack meets one of the following: MS, NMOSD, MOGAD, ADEM, clinically isolated syndrome, demyelinating encephalopathy, demyelinating myelitis, or brainstem encephalitis (see below A-E);\n3. Agree to participate in this study and sign the informed consent form.\n\nExclusion Criteria:\n\n1. History of tumors or diagnosis of central nervous system tumors;\n2. Infectious lesions of the central nervous system;\n3. Hereditary, metabolic, toxic, vascular, or traumatic demyelinating diseases of the brain\u002Fspinal cord;\n4. Non-compliance with treatment and follow-up.","65 Years",{"count":203,"type":22},450,"The goal of this observational study is to learn about pathogenesis and clinical prognosis of CNS IIDD in the Chinese population and to provide evidence-based clues for clinical treatment decisions.\n\nThe main questions it aims to answer are:\n\nQuestion 1: Clarify the clinical characteristics and prognostic factors of various diseases (MS, NMOSD, MOGAD, etc.) within IIDD in the Chinese population.\n\nQuestion 2: Analyze the relationship between biomarkers and the occurrence, progression, and prognosis of CNS IIDD cases in our hospital.\n\nParticipants will\n\n1. Receive the recommended diagnosis and treatment plans from current international and national guidelines or expert consensus, without additional special interventions.\n2. Receive clinical evaluation, follow-up, and management from dedicated neuroimmunology specialists.",[206,207,123,208,29,209],"Multiple Sclerosis, MS","Neuromyelitis Optica Spectrum Disorders","Acute Disseminated Encephalomyelitis","Demyelinating Disorder",[211,212],"CNS IIDD","follow-up","2024-08-02",{"date":215,"type":40},"2024-08-07",{"date":217,"type":40},"2024-01-01",{"date":219,"type":22},"2035-12-31",{"name":221,"class":47},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":228,"eligibilityCriteria":229,"healthyVolunteers":117,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":232,"conditions":233,"keywords":239,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":48},"100454970","ms-researchbiomarkers-100454970","NCT05204459","MS-ResearchBiomarkerS","Investigating the Longitudinal Relationships Between Visual Pathway Injury, Radiological and Blood Biomarkers in Multiple Sclerosis and Related Disorders","MS-ReBS","Inclusion Criteria:\n\n* Subjects who meet any one of the following diagnostic criteria:\n\n  * Diagnosis of MS, CIS,or RIS based on the 2017 revised McDonald criteria.\n  * Diagnosis of NMOSD based on the 2015 revised NMOSD consensus diagnostic criteria.\n  * Diagnosis of myelin oligodendrocyte glycoprotein (MOG)-related encephalomyelitis, optic neuritis, or other associated disease.\n  * Diagnosis of neurological disorders other than MSRD.\n  * Healthy volunteer.\n* Age ≥18.\n* Able to give informed consent.\n\nExclusion Criteria:\n\n* Patients will be excluded from the MRI portions of the study if they have a contraindication to MRI(metallic implantsor foreign bodies, claustrophobia, MRI-incompatible pacemakers, MRI- incompatible prosthetic heart valves).\n* Patients will be excluded from the MRI portions of the study if they are pregnant, but their demographic, clinical information,and disability measures may still be captured under the study.\n* Patients will be excluded from the visual assessment portions of the study if they have had any recent ocular surgery (within the past two months), refractive errors of greater than or equal to ±6 diopters or other eye diseases that may affect or confound OCT\u002FOCTA measurements (ex., age-related macular degeneration, advanced geographic atrophy, diabetic retinopathy, glaucoma).",{"count":231,"type":22},1000,"This study is being conducted to investigate risk factors for disability progression in Multiple Sclerosis and related disorders (MSRD). The primary goal is to assess whether combining information from visual assessment, blood markers, as well as historical and ongoing longitudinal MRIs of the brain, orbit (the part of the skull where eyes are located), and\u002For spinal cord can predict changes in quantitative disability measures related to MSRD and neurological disease.",[28,89,234,235,29,124,207,123,236,237,238],"Multiple Sclerosis, Primary Progressive","Multiple Sclerosis, Secondary Progressive","Neurologic Autoimmune Disease","Neurologic Disorder","Healthy Aging",[28,89,234,235,29,124,207,240,236,237,238],"Myelin oligodendrocyte glycoprotein antibody-associated disease","2024-02-05",{"date":243,"type":40},"2024-02-06",{"date":245,"type":40},"2021-11-11",{"date":247,"type":22},"2041-11-11",{"name":249,"class":47},"Cedars-Sinai Medical Center",{"id":251,"slug":252,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":256,"eligibilityCriteria":257,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":258,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":260,"conditions":261,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":48},"100451120","china-national-registry-of-neuro-inflammatory-diseases-100451120","NCT05154370","China National Registry of Neuro-Inflammatory Diseases","China National Registry of Neuro-Inflammatory Diseases: a Prospective Cohort Study","CNRID","Inclusion Criteria:\n\n* 1\\. No requirement for age and sex\n* 2\\. Need to meet the diagnosis of at least one IDD (clinically isolated syndrome (CIS)\u002Fmultiple sclerosis (MS)\u002Fneuromyelitis optica spectrum disorder (NMOSD)\u002FMOG antibody-associated disease (MOGAD)\u002Facute disseminated encephalomyelitis (ADEM).\n* 3\\. Signed informed consent form.\n\nExclusion Criteria:\n\n* Those with severe mental disease unable to cooperate with the examination and\u002For follow-up.\n* Any patient (or the patient's legal representative) who is unable or refuses to sign informed consent.",{"count":259,"type":22},10000,"Central nervous system (CNS) idiopathic inflammatory demyelinating diseases (IDD) are mainly diseases caused by autoimmune factors that result in CNS demyelination damage and loss. It tends to accumulate in the brain, spinal cord and optic nerves. Multiple sclerosis (MS), clinically isolated syndrome (CIS), neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and acute disseminated encephalomyelitis (ADEM) are all common IDDs of the CNS. Besides, primary angiitis of the central nervous system (PACNS), autoimmune glial fibrillary acidic protein astrocytopathy (GFAP-A), etc. may also be included because they are important differential diagnoses. This study will establish a large prospective cohort study database of Chinese IDD, which will record detailed electronic information on IDD patients, including demographic and socioeconomic data, medical history, clinical information, medication, and relevant examination results. The long-term observational study will be used to understand the natural history of disease, disability progression rates, imaging and biological indicators, long-term treatment approaches and prognosis of Chinese patients with IDD, to find predictive markers for IDD progression and prognosis, and to identify factors that influence the treatment and prognosis of patients with IDD.",[28,122,29,262,208,263,264],"CNS Demyelinating Autoimmune Diseases","Primay Angiitis of the Central Nervous System","Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy","2023-07-19",{"date":267,"type":40},"2023-07-21",{"date":269,"type":40},"2021-12-15",{"date":271,"type":22},"2026-11-01",{"name":273,"class":47},"Beijing Tiantan Hospital"]